Stock Forecast: The Market is Sleeping on Eli Lilly's Next $1 Trillion Opportunity24/7 Wall Street • 08/19/26
Eli Lilly, Stock Of The Day, Is Erasing Novo's Early Lead In Weight-Loss PillsInvestors Business Daily • 08/18/26
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?Zacks Investment Research • 08/17/26
Eli Lilly Just Scored a European Weight Loss Pill Approval -- and the Growth Story Keeps Getting BiggerThe Motley Fool • 08/14/26
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting BiggerThe Motley Fool • 08/14/26
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?Zacks Investment Research • 08/13/26
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)Seeking Alpha • 08/12/26
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutideMarket Watch • 08/12/26
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutideReuters • 08/12/26
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black marketPRNewsWire • 08/12/26